Odyssey Reports Wider Q2 Loss Of $52 Mln As OD-001 Advances In Phase 2 Studies
Odyssey Therapeutics (ODTX) reported a wider Q2 2026 net loss of $52.8M, up from $41.2M a year earlier, driven by higher external R&D spending. Q2 R&D was $36.2M versus $30.2M in 2025. Cash and marketable securities totaled $433.1M, expected to fund operations into 2028. Pipeline updates include OD-001 Phase 2a expansion and further trials in 2026.
How this was made
The 30-second read
Why it matters
Q2 results show increased spending and a wider net loss, while pipeline updates provide near-to-mid term catalysts: OD-001 Phase 2a expansion results in October 2026, Phase 2b monotherapy and Phase 2a combination in 2H 2026, and OD-002 IND-enabling studies concluding in 2H 2026 with Phase 1/2 starting in 1H 2027.
Market read
Traders get a fresh snapshot of cash burn (wider net loss and higher R&D) plus concrete upcoming clinical milestones and a runway estimate into 2028.
What to watch
The article does not quantify trial enrollment, costs per patient, or any interim efficacy signals, so the market may focus more on cash burn trajectory than on the calendar milestones.
Background
Odyssey Therapeutics is a clinical-stage biopharma that began Nasdaq trading in May 2026 and is advancing autoimmune/inflammatory programs including OD-001 and OD-002.
Ticker impact
Odyssey Therapeutics reported Q2 net loss of $52.8M, higher R&D spend, and outlined OD-001 and OD-002 Phase 2/1-2 timelines.
Likely modest downside bias on burn concerns, partially offset by continued Phase 2 progress and runway visibility.
The article discloses a larger net loss and higher R&D expense, but also provides cash runway guidance and specific upcoming trial milestones.
Market effects
Adds incremental read-through on autoimmune/inflammation biotech funding needs and typical Phase 2 execution timelines.
Limited, as the disclosure is company-specific for a Nasdaq-listed clinical-stage biotech.
Low, no cross-border regulatory or partnership details disclosed.
Counterpoint
The wider loss may reflect planned external R&D scaling for OD-001/OD-002, which could de-risk later-stage timelines if execution stays on schedule.
Key entities
- companyOdyssey Therapeutics Inc.
Clinical-stage biopharmaceutical company reporting Q2 financials and providing OD-001/OD-002 development timelines.
- drug_candidateOD-001
Lead candidate with Phase 2a expansion study completed for ulcerative colitis; additional Phase 2 studies planned in 2H 2026.
- drug_candidateOD-002
Candidate for cutaneous lupus erythematosus; IND-enabling studies expected to conclude in 2H 2026 and Phase 1/2 planned for 1H 2027.
- analystWedbush (David Nierengarten)
Reiterated an Outperform rating and set a $30 price target.
